09 December 2018
: Case report
Acyclovir Neurotoxicity in a Peritoneal Dialysis Patient: Report of a Case and Review of the Pharmacokinetics of Acyclovir
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis)
Seyed-Ali Sadjadi1ABCDEG*, Surakshya Regmi1BG, Tony Chau2EFDOI: 10.12659/AJCR.911520
Am J Case Rep 2018; 19:1459-1462
Abstract
BACKGROUND: The elderly population in the United States and the world is rapidly increasing. With aging, immunity and kidney function decrease, thus predisposing people to viral illnesses for which there is no effective prophylaxis. Herpes zoster afflicts the elderly and other immunocompromised patients, like those with end-stage renal disease, transplant recipients, and cancer patients, causing significant morbidity and sometimes mortality. Treating herpes zoster becomes problematic when the regular pharmacokinetics of the antiviral drugs are disturbed.
CASE REPORT: An 83-year-old African American man with end-stage kidney disease (ESRD) and on chronic peritoneal dialysis (PD) developed herpes zoster, for which he received the manufacturer-recommended intravenous dose of acyclovir. Shortly after taking the medication, he developed confusion, disorientation, and visual hallucinations. He was switched from PD to hemodialysis (HD), with successful recovery. Examination of the cerebrospinal fluid for meningitis and imaging studies of the head were negative. Serum levels of acyclovir were elevated.
CONCLUSIONS: Even when the acyclovir dose is properly adjusted for kidney function based on the current manufacturer’s recommendations, it can cause neurotoxicity. Here, we discuss the pharmacokinetics of acyclovir and make some recommendations with regard to dose adjustment in patients with ESRD.
Keywords: acyclovir, Dialysis, Neurotoxicity Syndromes
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946414
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.944665
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946514
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946456
Most Viewed Current Articles
21 Jun 2024 : Case report
90,010
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,284
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,908
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,715
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030